Loading in 2 Seconds...
Loading in 2 Seconds...
In the forefront of the battle against emerging infectious diseases. Avraham Shimon Marilus CEO Dorit Arad CSO and Founder . Mission. Be ready to Rapidly detect Prevent the spread Provide better treatment for infectious diseases particularly those that impose world pandemics threat.
Avraham Shimon Marilus CEO
Dorit Arad CSO and Founder
Be ready to
for infectious diseases
particularly those that impose world pandemics threat
Novel (Based on viral enzyme detection)
Rapid (only 3 minutes detection)
Detection of live viruses
For pandemic causing viruses to prevent their spread
For existing viruses to provide a better care
The BDC Group
Prof Max Herzberg
Prof. Christian Policard
Ms. Nicole Rieunier-Burle
The MND Team
Mr. AvrahamMarilus CEO and Chairman
Dr. Dorit Arad – CSO and founder
Dr. OurielFaktor VP R&D
Prof. Max Herzberg - Director
David Greenberg M.D.,
Medical director, Soroka
Prof. Dana Wolf, Hadassah Hospital, Israel
Specific Enzymatic Based assay
Partner – Avian Flu (poultry)
BMD Multiplex Meningitis
MND single test
Partner – emerging pandemic kit
for outbreak control
MND Avian Flu (Humans)
Each year in the United States 10 million to 15 million illnesses are attributed to Enterovirus
300,000 Lumbar Punctures are performed in the US every year. This number will grow when there will be a fast detection tool to diagnose the disease.
Current Gold Standard
The “gold standard” for Enterovirus detection is Tissue culture which takes 3 days. RT-PCR takes 5-24 hours
Current Development Status
Proof of concept completed in 2007
Pre-clinical studies planned for Q3 2008
Over 100 clinical CSF samples tested successfullyMeningitis Rapid Detection Kit
1. Persistent viruses (Meningitis, Enterovirus, CMV andRhinovirus)
2. Emerging viruses (Avian Flu, SARS).
MND’s intellectual property includes three pending patents on the detection method, compositions of matters for a wide range of viruses including HCV and detection of avian influenza.
Unique molecular design techniques (QCT) enable the creation of effective molecules, specific to each disease agent, for treatment and detection. Experience in the development of rapid testing formatsIP & knowhow
Creating leverage through MND’s novel IP
Advance MND platform and pipeline products for the detection of: Avian Influenza, CMV, HCV and Foot and Mouth disease.
Complete co-development of a Multiplex Detection Kit with BMD (BioMedical Diagnostics, France).
Establish strategic partnerships with leading Pharma.Company Goals 2008-2010